LGM
Logos Global Management Portfolio holdings
AUM
$749M
1-Year Return
18.94%
This Quarter Return
-5.41%
1 Year Return
+18.94%
3 Year Return
+431.72%
5 Year Return
+481.1%
10 Year Return
–
AUM
$868M
AUM Growth
-$82.4M
(-8.7%)
Cap. Flow
+$19M
Cap. Flow
% of AUM
2.19%
Top 10 Holdings %
Top 10 Hldgs %
50.33%
Holding
70
New
16
Increased
12
Reduced
15
Closed
15
Top Buys
| 1 |
argenx
ARGX
|
$58.1M |
| 2 |
Merus
MRUS
|
$50.3M |
| 3 |
Revolution Medicines
RVMD
|
$46.6M |
| 4 |
Disc Medicine
IRON
|
$41.7M |
| 5 |
MoonLake Immunotherapeutics
MLTX
|
$33M |
Top Sells
| 1 |
Immunocore
IMCR
|
$58.5M |
| 2 |
Dyne Therapeutics
DYN
|
$51.7M |
| 3 |
Sarepta Therapeutics
SRPT
|
$39.5M |
| 4 |
Immunovant
IMVT
|
$31.7M |
| 5 |
Geron
GERN
|
$29.7M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Spyre Therapeutics
SYRE
$1.04B
| $13.5M | 1.09% |
575,000
+325,000
| +130% | +$7.64M |
|
27
enGene Holdings
ENGN
$245M
| $11.3M | 0.91% |
1,200,000
+400,000
| +50% | +$3.77M |
|
|
CYBN
28
Cybin
CYBN
$141M
| $10.8M | 0.87% |
1,052,632
| – | – |
|
29
Skye Bioscience
SKYE
$115M
| $10.4M | 0.84% |
+1,301,518
| New | +$10.4M |
|
|
ELEV
30
DELISTED
Elevation Oncology
ELEV
| $10.4M | 0.84% |
3,850,000
+2,850,000
| +285% | +$7.7M |
|
|
31
Dyne Therapeutics
DYN
$1.87B
| $9.35M | 0.75% |
265,000
-1,465,000
| -85% | -$51.7M |
|
32
Biohaven
BHVN
$1.69B
| $8.68M | 0.7% |
+250,000
| New | +$8.68M |
|
33
Relay Therapeutics
RLAY
$690M
| $8.48M | 0.68% |
+1,300,000
| New | +$8.48M |
|
34
Trevi Therapeutics
TRVI
$873M
| $8.34M | 0.67% |
2,800,000
+600,000
| +27% | +$1.79M |
|
35
Rocket Pharmaceuticals
RCKT
$347M
| $7.54M | 0.61% |
350,000
-950,000
| -73% | -$20.5M |
|
|
CMPS
36
Compass Pathways
CMPS
$493M
| $7M | 0.56% |
1,159,030
+901,050
| +349% | +$5.44M |
|
37
Avalo Therapeutics
AVTX
$136M
| $6.72M | 0.54% |
+539,079
| New | +$6.72M |
|
38
Lineage Cell Therapeutics
LCTX
$276M
| $4.69M | 0.38% |
4,700,000
-1,550,000
| -25% | -$1.55M |
|
|
ATYR
39
aTyr Pharma
ATYR
$539M
| $4.68M | 0.38% |
3,000,000
-100,000
| -3% | -$156K |
|
40
Astria Therapeutics
ATXS
$402M
| $4.55M | 0.37% |
500,000
-744,960
| -60% | -$6.78M |
|
|
RAPP
41
Rapport Therapeutics
RAPP
$560M
| $4.37M | 0.35% |
+208,910
| New | +$4.37M |
|
42
NextCure
NXTC
$13.1M
| $3.98M | 0.32% |
208,333
+47,916
| +30% | +$914K |
|
43
Neumora Therapeutics
NMRA
$264M
| $2.95M | 0.24% |
300,000
-82,345
| -22% | -$809K |
|
|
ALLK
44
DELISTED
Allakos
ALLK
| $2.9M | 0.23% |
2,900,000
| – | – |
|
45
Adverum Biotechnologies
ADVM
$66.5M
| $2.86M | 0.23% |
416,666
-1,083,333
| -72% | -$7.43M |
|
46
Applied Therapeutics
APLT
$67.8M
| $2.66M | 0.21% |
600,000
-750,000
| -56% | -$3.33M |
|
47
Cartesian Therapeutics
RNAC
$265M
| $2.43M | 0.2% |
+90,000
| New | +$2.43M |
|
48
Unicycive Therapeutics
UNCY
$75.4M
| $1.74M | 0.14% |
346,993
| – | – |
|
49
IO Biotech
IOBT
$121M
| $578K | 0.05% |
493,827
| – | – |
|
|
BOLD
50
Boundless Bio
BOLD
$25.7M
| $433K | 0.03% |
117,806
-82,194
| -41% | -$302K |
|